Collaborative Arrangements and Licensing Agreements, Novartis (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Aug. 31, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue		$ 133,093	$ 160,079	$ 370,450	$ 438,983
Novartis [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Cumulative payments received		425,000		425,000
Novartis [Member] | Maximum [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Next prospective milestone		75,000		$ 75,000
Novartis [Member] | Pelacarsen [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue	$ 25,000	$ 25,000
Percentage enrollment in Lp(a) HORIZON Phase 3 cardiovascular outcome study	50.00%	50.00%		50.00%